Related Experiment Video

Updated: May 27, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management

Rebecca L Brown1

  • 1Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, IL 60637, USA. rbrown3@medicine.bsd.uchicago.edu

Targeted Oncology
|November 22, 2011
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) are effective cancer drugs but can cause thyroid dysfunction. Routine monitoring and potential treatment are necessary for patients receiving TKI therapy.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Tyrosine kinase inhibitors (TKIs) represent a significant advancement in cancer treatment.
  • While effective, TKIs are associated with notable side effects, including fatigue and hypertension.
  • Thyroid dysfunction is an increasingly recognized toxicity of certain TKIs.

Purpose of the Study:

  • To comprehensively review the literature on TKI-induced thyroid dysfunction.
  • To explore the mechanisms underlying this adverse effect.
  • To assess the clinical significance and treatment controversies of TKI-induced thyroid dysfunction.

Main Methods:

  • Literature review of studies evaluating TKI-induced thyroid dysfunction.
  • Analysis of potential mechanisms of thyroid toxicity.
  • Assessment of clinical impact and treatment strategies.

Main Results:

  • TKI-induced thyroid dysfunction is a common toxicity associated with specific TKI agents.
  • Mechanisms of thyroid dysfunction are multifactorial and under investigation.
  • Clinical significance varies, necessitating monitoring and potentially thyroid hormone replacement therapy.

Conclusions:

  • TKI-induced thyroid dysfunction is a clinically relevant side effect requiring vigilant monitoring.
  • Understanding the mechanisms is crucial for managing this toxicity.
  • Evidence supports the need for thyroid hormone treatment in symptomatic cases, though controversies remain.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...